John Galla, MD
Interventional Cardiology · Mobile, ALNPI 1881743607
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,758 of the $81,521 with a category attached, or 84.3%. Johnson & Johnson accounts for 90.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $37,808 and has fallen 95.5% since, to $1,691 in 2025. Among interventional cardiology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $250.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$74K
- Medtronic$3K
- Boston Scientific$1K
- Abbott$1K
- Philips North America LLC$1K
- Edwards Lifesciences$272
- plus $1K from 21 others
Across 8 payments — averaging $1413.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$11K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$68,75884%
- Travel & lodging$2,9914%
- Food & beverage$9,47312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 150 | $73,620 |
| Medtronic(2 entities) | 79 | $2,641 |
| Boston Scientific | 14 | $1,260 |
| Abbott | 34 | $1,248 |
| Philips North America LLC | 10 | $1,054 |
| Edwards Lifesciences | 5 | $272 |
| Penumbra, Inc. | 3 | $192 |
| Shockwave Medical, Inc | 3 | $181 |
| Janssen Scientific Affairs, LLC | 1 | $150 |
| Biotronik Inc. | 1 | $115 |
| Abiomed | 2 | $103 |
| Contego Medical, Inc | 1 | $92 |
| Cardiovascular Systems Inc. | 2 | $90 |
| Bard Peripheral Vascular, Inc. | 1 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Veryan Medical Incorporated | 1 | $57 |
| Novartis | 3 | $55 |
| Baxter Healthcare | 1 | $44 |
| Boehringer Ingelheim | 2 | $40 |
| Pfizer | 2 | $35 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Terumo Medical Corporation | 1 | $20 |
| Amgen | 1 | $18 |
| Merck | 1 | $17 |
| Inspiremd Ltd | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Reflow Medical Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$71,915
- COREVALVE EVOLUT R$950
- GENERAL - THERAPIES$607
- Labosys$479
- CoreValve Evolut$267
- Mitra Clip system$258
- Lasers$249
- NAVITOR$244
- Orsiro Mission$115
- LOTUS EDGE$104
How this compares
$81,521 in reported general payments places this provider in the 95th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 177 | $182,550 |
| XareltoRivaroxaban | 183 | $180,518 |
| EntrestoSacubitril/Valsartan | 66 | $81,183 |
| Repatha SureclickEvolocumab | 32 | $29,718 |
| FarxigaDapagliflozin Propanediol | 18 | $10,084 |
| ClopidogrelClopidogrel Bisulfate | 415 | $5,745 |
| Ranolazine ErRanolazine | 32 | $4,179 |
| Clonidine | 17 | $2,948 |
| Rosuvastatin Calcium | 143 | $2,804 |
| Carvedilol | 323 | $2,587 |
| Atorvastatin Calcium | 229 | $2,522 |
| Metoprolol Succinate | 133 | $2,283 |
| Losartan Potassium | 179 | $1,933 |
| Amlodipine Besylate | 220 | $1,748 |
| Potassium Chloride | 87 | $1,630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $182,550177 claims |
| Johnson & JohnsonXarelto | $73,620 | $180,518183 claims |
| NovartisEntresto | $55 | $81,18366 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Mobile
- Ahmed SubahiMobile$37K
- Mir HashimiMobile$24K
- Mohammed ElzeneiniMobile$23K
- Benjamin CitrinMobile$11K
- James GladdenMobile$9K
- Stanley ThorntonMobile$7K
- Michael MonsonMobile$7K
- Kevin DeandradeMobile$7K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.